5 Results for "

PI103

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "PI103" in MCE Product Catalog:

33
33 Cited Publications
Cat. No.: HY-10115
CAS No.: 371935-74-9
Purity:  99.82%
Research Areas:  

Cancer

PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-10115A
CAS No.: 371935-79-4
Purity:  98.55%
Research Areas:  

Cancer

PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .
loading...
    loading...
Cat. No.: HY-10115AR
CAS No.: 371935-79-4
Research Areas:  

Cancer

PI-103 (Hydrochloride) (Standard) is the analytical standard of PI-103 (Hydrochloride). This product is intended for research and analytical applications. PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .
loading...
    loading...
Cat. No.: HY-10115R
CAS No.: 371935-74-9
Research Areas:  

Cancer

PI-103 (Standard) is the analytical standard of PI-103. This product is intended for research and analytical applications. PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy .
loading...
    loading...
Cat. No.: HY-144876
CAS No.: 2581114-71-6
Purity:  98.02%
Research Areas:  

Cancer

RIDR-PI-103 is a reactive oxygen species (ROS)-induced agent release proagent with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation .
loading...
    loading...